PERL Continuous Glucose Monitoring (CGM) Study

Completed · Has a placebo group

Conditions studied: Diabetic Nephropathies

In brief

Seven-point capillary profiles have shown that mean glucose correlates with both diabetic retinopathy and nephropathy risk. However, there remains great controversy as to whether the degree of variability around mean glucose may also contribute to these microvascular complications. The PERL trial (NCT02017171), testing whether treatment with allopurinol can slow down kidney function loss in type 1 diabetes, provides a unique opportunity to assess the role of glycemic variability in the progression of diabetic kidney disease in individuals who already have mild to moderate kidney disease. By applying Continuous Glucose Monitoring (CGM) in the PERL Study population, the investigators will be able to better understand how metrics of glycemia (mean, time above and below range, and various measures of variability) are associated with renal outcomes in the PERL population as a whole, but also in important subgroups (e.g., albuminuric vs. normoalbuminuric subjects with ongoing GFR decline, allopurinol vs. placebo arms). The nvestigators also aim to obtain precise information on the range of blood glucose corresponding to any given HbA1c value in this population since previous studies generally excluded patients with renal disease.

Key facts

Study ID

NCT03334318

Run by

Joslin Diabetes Center

People needed

175

Starts

2017-10-01

Expected to finish

2021-12-31

Last updated by the study team

2022-03-29

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Being an active participant in the PERL clinical trial

You may not qualify if…

• Having completed PERL Visit 16
• Pregnancy
• History of skin reactions in relation to the application of Abbott Freestyle Libre Pro

Where it is running

• Barbara Davis Center / University of Colorado Denver — Aurora, Colorado, United States
• Emory University - Grady Memorial Hospital — Atlanta, Georgia, United States
• Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States
• Joslin Diabetes Center — Boston, Massachusetts, United States
• Brehm Center for Diabetes Research / University of Michigan — Ann Arbor, Michigan, United States
• Henry Ford Health System — Detroit, Michigan, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• Washington University — St Louis, Missouri, United States
• ICAHN School of Medicine at Mount Sinai — New York, New York, United States
• SUNY Upstate Medical University — Syracuse, New York, United States
• Albert Einstein College of Medicine / Montefiore Medical Center — The Bronx, New York, United States
• UT Southwestern Dallas — Dallas, Texas, United States
• Virginia Mason Medical Center — Seattle, Washington, United States
• University of Washington — Seattle, Washington, United States
• Providence Sacred Heart Medical Center — Spokane, Washington, United States
• Unversity of Calgary — Calgary, Alberta, Canada
• University of Alberta — Edmonton, Alberta, Canada
• BC Diabetes — Vancouver, British Columbia, Canada
• University of Toronto — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.